Back to discover
Drug

Ticlopidine

In clinical development
Emerging researchLate-stage developmentRising momentum

Also known as Ticlid, Ticlopidina, Ticlopidine Hydrochloride, Ticlopidinum.

RxNorm10594ChEMBLCHEMBL833ATCB01AC05UNIIOM90ZUW7M1
3
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.

Research2020-06-01JAMA

A Fixed-sequence, Open-label Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Subjects

Clinical trial2017-11-27Completed · ClinicalTrials.gov

A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg/Day Versus Ticlopidine 200 mg/Day in Patients With Peripheral Arterial Disease - With Extended Treatment of Clopidogrel 75 mg/Day for 40 Weeks

Clinical trial2011-05-01Completed · ClinicalTrials.gov

Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol

Clinical trial2010-12-01Completed · ClinicalTrials.gov

A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg Once Daily With a 300 mg Loading Dose Versus Ticlopidine 100 mg Twice Daily in Patients With Stable Angina or Old (Healed) Myocardial Infarction to Which Percutaneous Coronary Intervention is Being Planned - With Extended Treatment of Clopidogrel 75 mg Once Daily for 40 Weeks in a Patients' Subset

Clinical trial2010-08-01Completed · ClinicalTrials.gov

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.

Research2010-03-01Journal of the American College of Cardiology

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.

Research2007-01-29Circulation

African American Antiplatelet Stroke Prevention Study

Clinical trial2005-06-24Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ticlopidine
Aliases & brands
TiclidTiclopidinaTiclopidine HydrochlorideTiclopidinum
RxNorm CUI
10594
ChEMBL ID
CHEMBL833
ATC codes
B01AC05
UNII
OM90ZUW7M1

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2017
4
Late-stage (III+)
5
Completed
PHASE DISTRIBUTIONn = 5
Phase 11Phase 32Phase 42

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol

CompletedPH IVTurku University Hospitaln=122010

African American Antiplatelet Stroke Prevention Study

CompletedPH IVNational Institute of Neurological Disorders and Stroke (NINDS)2005

A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg/Day Versus Ticlopidine 200 mg/Day in Patients With Peripheral Arterial Disease - With Extended Treatment of Clopidogrel 75 mg/Day for 40 Weeks

CompletedPH IIISanofin=4312011

A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg Once Daily With a 300 mg Loading Dose Versus Ticlopidine 100 mg Twice Daily in Patients With Stable Angina or Old (Healed) Myocardial Infarction to Which Percutaneous Coronary Intervention is Being Planned - With Extended Treatment of Clopidogrel 75 mg Once Daily for 40 Weeks in a Patients' Subset

CompletedPH IIIKey trialSanofin=1,0032010

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Fixed-sequence, Open-label Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Subjects

CompletedPH IJanssen Research & Development, LLCn=162017

A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg/Day Versus Ticlopidine 200 mg/Day in Patients With Peripheral Arterial Disease - With Extended Treatment of Clopidogrel 75 mg/Day for 40 Weeks

CompletedPH IIISanofin=4312011

Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol

CompletedPH IVTurku University Hospitaln=122010

A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg Once Daily With a 300 mg Loading Dose Versus Ticlopidine 100 mg Twice Daily in Patients With Stable Angina or Old (Healed) Myocardial Infarction to Which Percutaneous Coronary Intervention is Being Planned - With Extended Treatment of Clopidogrel 75 mg Once Daily for 40 Weeks in a Patients' Subset

CompletedPH IIIKey trialSanofin=1,0032010

African American Antiplatelet Stroke Prevention Study

CompletedPH IVNational Institute of Neurological Disorders and Stroke (NINDS)

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20072020
Major research themes1
Purinergic P2 Receptor Antagonists1
Journals, researchers & institutions
Top journals
  • Circulation1
  • JAMA1
  • Journal of the American College of Cardiology1
Leading researchers
  • Angiolillo DJ2
  • Bass TA2
  • Bernardo E2
  • Ahn CM1
  • Alfonso F1
  • Capodanno D1
  • Charlton RK1
  • Cho DK1
Leading institutions
free-text, unnormalised
  • Dankook University Hospital1
  • Gangnam Severance Hospital1
  • Gangneung Asan Hospital1
  • Kangwon National University School of Medicine1
  • Myongji Hospital1
  • National Health Insurance Service Ilsan Hospital1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
Coronary Artery Disease2

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Aspirin

Studied across 7 of the same disease areas as Ticlopidine in the shared literature.

7 shared diseases2 shared papers
Clopidogrel

Studied across 7 of the same disease areas as Ticlopidine in the shared literature.

7 shared diseases2 shared papers
Sirolimus

Studied across 3 of the same disease areas as Ticlopidine in the shared literature.

3 shared diseases1 shared paper
Ticagrelor

Studied across 3 of the same disease areas as Ticlopidine in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials